# Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

> **NCT04430452** · PHASE2 · RECRUITING · sponsor: **Mary Feng, MD** · enrollment: 21 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma
- Stage III Hepatocellular Carcinoma AJCC v8
- Stage IIIA Hepatocellular Carcinoma AJCC v8
- Stage IIIB Hepatocellular Carcinoma AJCC v8
- Stage IV Hepatocellular Carcinoma AJCC v8
- Stage IVA Hepatocellular Carcinoma AJCC v8
- Stage IVB Hepatocellular Carcinoma AJCC v8

## Interventions

- **BIOLOGICAL:** Durvalumab
- **RADIATION:** Hypofractionated Radiation Therapy
- **BIOLOGICAL:** Tremelimumab

## Key facts

- **NCT ID:** NCT04430452
- **Lead sponsor:** Mary Feng, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-04
- **Primary completion:** 2028-07-31
- **Final completion:** 2029-07-31
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04430452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04430452, "Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04430452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*